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Adenosine signaling via A1 receptor (A1R) and A2A receptor (A2AR) has shown promise in revealing
potential targets for neuroprotection in cerebral ischemia. We recently showed a novel mechanism by
which A1R activation with N6-cyclopentyl adenosine (CPA) induced GluA1 and GluA2 AMPA receptor
(AMPAR) endocytosis and adenosine-induced persistent synaptic depression (APSD) in rat hippocampus.
This study further investigates the mechanism of A1R-mediated AMPAR internalization and hippocampal
slice neuronal damage through activation of protein phosphatase 1 (PP1), 2A (PP2A), and 2B (PP2B) using
electrophysiological, biochemical and imaging techniques. Following prolonged A1R activation, GluA2
internalization was selectively blocked by PP2A inhibitors (okadaic acid and fostriecin), whereas in-
hibitors of PP2A, PP1 (tautomycetin), and PP2B (FK506) all prevented GluA1 internalization. Additionally,
GluA1 phosphorylation at Ser831 and Ser845 was reduced after prolonged A1R activation in hippo-
campal slices. PP2A inhibitors nulliﬁed A1R-mediated downregulation of pSer845-GluA1, while PP1 and
PP2B inhibitors prevented pSer831-GluA1 downregulation. Each protein phosphatase inhibitor also
blunted CPA-induced synaptic depression and APSD. We then tested whether A1R-mediated changes in
AMPAR trafﬁcking and APSD contribute to hypoxia-induced neuronal injury. Hypoxia (20 min) induced
A1R-mediated internalization of both AMPAR subunits, and subsequent normoxic reperfusion (45 min)
increased GluA1 but persistently reduced GluA2 surface expression. Neuronal damage after hypoxia-
reperfusion injury was signiﬁcantly blunted by pre-incubation with the above protein phosphatase in-
hibitors. Together, these data suggest that A1R-mediated protein phosphatase activation causes persis-
tent synaptic depression by downregulating GluA2-containing AMPARs; this previously undeﬁned role of
A1R stimulation in hippocampal neuronal damage represents a novel therapeutic target in cerebral
ischemic damage.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
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four known G-protein-coupled adenosine receptors (A1, A2A, A2B,
and A3), A1 and A2A receptors (A1R, A2AR) have well classiﬁed
neuromodulatory functions in the central nervous system, with
opposing inhibitory and excitatory actions, respectively (Sichardt
and Nieber, 2007). During situations of neuronal stress, extracel-
lular adenosine concentrations increase drastically from extracel-
lular ATP breakdown and adenosine extrusion from stressed cells
(Dale et al., 2000; Pearson et al., 2001). High levels of adenosine in
the hippocampus cause increased A1R activation and subsequent
synaptic depression (Chen et al., 2014). A1R-induced synaptic
depression is thought to afford neuroprotection to ischemic cells by
preventing excitotoxicity during metabolic stress presynaptically
by inhibiting glutamate release (Liu et al., 2006; Obrietan et al.,
1995) and postsynaptically by reducing neuronal excitability
(Cunha, 2005).
We recently showed that A1R activation causes rapid clathrin-
mediated endocytosis of excitatory a-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid receptors (AMPARs) through both a
physical and functional interaction (Chen et al., 2014). Speciﬁcally,
A1Rs interact with GluA1 and GluA2 AMPAR subunits to induce
their endocytosis. We showed that p38 mitogen-activated protein
kinase (MAPK), c-Jun N-terminal kinase (JNK) and protein phos-
phatase 2A (PP2A) inhibition prevented adenosine-induced GluA1-
and GluA2-containing AMPAR internalization, although inhibition
of p38 and JNK did not entirely prevent A1R-induced GluA1 inter-
nalization (Chen et al., 2014). Additionally, prolonged A1R activa-
tion induced adenosine-induced persistent synaptic depression
(APSD) in CA1 of rat hippocampal slices. However, the precise
cellular mechanism of APSDs in the hippocampus remains to be
established.
GluA1 plays an essential role in fast excitatory synaptic
transmission in the hippocampus, such as the induction of certain
forms of synaptic plasticity (Lee et al., 2010), and is present in a
majority of hippocampal neurons (Rogers et al., 1991). Of partic-
ular importance, GluA1 homomers are permeable to Ca2þ, and
their overexpression has been shown to play a role in ischemia-
induced neuronal death (Kwak and Weiss, 2006). Accordingly,
blockade of Ca2þ-permeable AMPARs (CP-AMPARs) has been
shown to reduce ischemia-induced neuronal death in the brain
(Noh et al., 2005). It follows that A1R-induced GluA1 internali-
zation may contribute in the short term (within minutes) to
prevent acute excitotoxicity during neurotoxic stimuli such as in
cerebral ischemia. However, whether changes in the levels of
GluA1 and GluA2 AMPAR surface expression are linked to
persistent A1R signaling that contributes to hippocampal
neuronal damage has never been previously studied. GluA1 sur-
face expression is known to be regulated in part by the phos-
phorylation state of two major C-terminal serine residues of
GluA1, namely Ser831 and Ser845, which control multiple func-
tions of GluA1 such as surface expression, synaptic translocation,
channel open probability, and channel conductance (Lee et al.,
2003). Phosphorylation of Ser831 and Ser845 by PKC/CaMKII
and PKA, respectively, has been shown to induce increased GluA1
surface expression and synaptic localization (Esteban et al., 2003;
Gu et al., 1996; He et al., 2011). Alternately, dephosphorylation of
Ser831 and Ser845 has also been shown to mediate a reduction in
the surface expression of GluA1 (Beattie et al., 2000; Lee et al.,
2010; Oh et al., 2006). We previously showed that A1R activa-
tion induced downregulation of phospho-Ser845 (pSer845) that
accompanies A1R-induced GluA1 endocytosis (Chen et al., 2014).
In the present study, we further examined the role of serine/
threonine phosphatases in modulating the phosphorylation of
Ser831 and Ser845 of GluA1 subunits. Three major serine/threo-
nine phosphatases present in hippocampal neurons are proteinphosphatase 1 (PP1), PP2A, and PP2B/calcineurin (Don Yi and
Simpkins, 2008), all of which have increased activity in hypoxia
and ischemia (Brust et al., 2006; Hedou et al., 2008; Shintani-
Ishida and Yoshida, 2011). PP1, PP2A, and PP2B have been
shown to play a role in different neuroprotective mechanisms and
cellular responses to neuronal insult conditions, as well as AMPAR
and N-methyl-D-aspartate receptor (NMDAR) modulation in the
hippocampus (Beattie et al., 2000; Belmeguenai and Hansel,
2005; Don Yi and Simpkins, 2008; Hedou et al., 2008). A1R
stimulation induces multiple intracellular signals, including the
recruitment of PP2A to the cellular membrane of hippocampal
neurons (Brust et al., 2006). Therefore, we hypothesized that PP1,
PP2A and PP2B function mediates A1R-induced GluA1 dephos-
phorylation, which contributes to A1R-induced GluA1 internali-
zation and persistent synaptic inhibition.
We tested this hypothesis using electrophysiological, biochem-
ical and confocal imaging analyses of rat hippocampal slices with
exposure to selective protein phosphatase inhibitor drugs in the
presence of N6-cyclopentyladenosine (CPA), a selective A1R agonist,
and hypoxia/reperfusion conditions. We found that inhibition of
PP1, PP2A, and PP2B reduced APSDs and GluA1 endocytosis in rat
hippocampal slices after CPA treatment, but PP2A inhibition
selectively prevented GluA2 internalization. Treatment with pro-
tein phosphatase inhibitors or A1R antagonist also reduced both
CPA-mediated and hypoxia/reperfusion-induced hippocampal
neuronal death. These results indicate a previously unrecognized
mechanism of neuronal death in the vulnerable tissue of the hip-
pocampus, whereby the A1R signaling through protein phospha-
tase activation triggers the formation of GluA2-deﬁcient AMPARs
on hippocampal membranes, which leads to increased hypoxia-
induced neuronal death.
2. Materials and methods
2.1. Animals and ethics statement
All animal care and experimental procedures were carried out in
accordancewith the National Institutes of Health Guide for the Care
and Use of Laboratory Animals (NIH publications No. 85-23, revised
1985), and also conformed to guidelines of the Canadian Council for
Animal Care (CCAC) under the supervision of the University of
Saskatchewan Committee on Animal Care and Supply (Approved
Animal Use Protocol Number: 20070090). The following experi-
mental design, analysis and reported number of research animals
used also complied with the ARRIVE guidelines for reporting ex-
periments involving animal use to ensure all efforts were made to
minimize animal suffering and the number of animals used in this
study (Kilkenny et al., 2010). Male SpragueeDawley rats (post-natal
18e30 days) were housed in cages in groups of three or four,
maintained at 20e24 C with a natural lightedark cycle. Rats were
purchased from Charles River Canada (Montreal, Quebec, Canada).
All animals had unlimited access to standard pelleted diet and tap
water.
2.2. Hippocampal slice preparation
Young male SpragueeDawley rats (post-natal18-30 days) were
anaesthetized with halothane and rapidly decapitated, with the
brains immediately excised and submerged in oxygenated, ice-cold
high-sucrose dissection medium containing the following (in mM):
87 NaCl, 25 NaHCO3, 25 glucose, 75 sucrose, 2.5 KCl, 1.25 NaH2PO4,
7.0 MgCl2, and 0.5 CaCl2 (Brust et al., 2007; Chen et al., 2014).
Hippocampal slices were taken at 400 mm thickness using a
vibrating tissue slicer (VTS1200S, Vibram Instruments, Germany),
and slicing was performed in the same ice-cold oxygenated
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at room temperature in oxygenated artiﬁcial cerebrospinal ﬂuid
(aCSF) containing the following (in mM): 126 NaCl, 2.5 KCl, 2.0
MgCl2, 1.25 NaH2PO4, 26 NaHCO3, 10 glucose, 2.0 CaCl2 (Brust et al.,
2007; Chen et al., 2014). Oxygenation was accomplished by
continually aerating the solution with 95% O2/5% CO2.
2.3. Drug treatments
Hippocampal slices were incubated in one of the following
treatments: dimethyl sulfoxide (DMSO, vehicle control, Sigma, St.
Louis, MO), fostriecin (20 nM, Tocris, Bristol, UK), okadaic acid
(3 nM, 20 nM, Tocris), tautomycetin (20 nM, Tocris), and FK506
(50 nM, Sigma). Fostriecin and okadaic acid are PP2A inhibitors,
tautomycetin is a PP1 inhibitor, and FK506 is a PP2B inhibitor. The
pharmacological inhibitor concentrations used are at least 10 times
the reported IC50 values or similar to those previously demon-
strated to be effective in hippocampal slices (Hedou et al., 2008;
Launey et al., 2004; Sharkey and Butcher, 1994; Uchino et al.,
2002; Walsh et al., 1997). N6-cyclopentyladenosine (CPA) was
used as a selective adenosine A1R agonist at 500 nM, and 8-
cyclopentyl-1,3-dipropylxanthine (DPCPX) (Sigma) was used as a
selective adenosine A1R antagonist at 500 nM. All drugs were
dissolved in DMSO (Sigma) before being added to aCSF. The ﬁnal
concentration of DMSO was <0.1% in each treatment and bath
incubation.
2.4. Electrophysiology
Hippocampal slices were submerged in an electrophysiology
recording chamber with constant perfusion of oxygenated aCSF
(3 ml/min) containing the appropriate drug treatment. As previ-
ously described (Brust et al., 2007, 2006; Chen et al., 2014), ﬁeld
excitatory postsynaptic potentials (fEPSPs) were evoked by ortho-
dromic stimulation of the Schaffer collateral pathway using a bi-
polar tungsten stimulating electrode, and fEPSP signals were
digitized at 10 kHz using Digidata 1440A interface board and
analyzed using Clampﬁt 9.0 (Axon Instruments, Foster City, CA). A
recording microelectrode ﬁlled with aCSF was placed in CA1 stra-
tum radiatum. The fEPSPs were evoked using 0.1 ms pulses every
30 s throughout each experiment. A stable baseline recording of at
least 20 min was used, followed by a 30 min CPA treatment or a
20 min hypoxic insult and a subsequent 1 h washout period.
Hypoxia was achieved by bubbling aCSF with 95% N2/5%CO2 for at
least 20 min, as previously described (Brust et al., 2006, 2007; Chen
et al., 2014). Although O2 was replaced with N2, the bubbling so-
lution was in an open container and the recording chamber was
open to air, so the recording solution was considered hypoxic. The
fEPSP slopes were normalized to themean of the 10 sweeps (5 min)
immediately preceding drug perfusion. Statistical signiﬁcance was
assessed using one-way analysis of variance (ANOVA) with
TukeyeKramer post-hoc test.
2.5. Biochemistry
Biochemical methods used are outlined in a recent report
(Chen et al., 2014). In short, following appropriate drug incubation,
brain slices were treated with CPA for 30 min or hypoxia for
20 min. For hypoxia-reperfusion studies, brain slices were placed
in normoxic aCSF solution for 45 min after the 20 min hypoxic
stimulation and prior to initiating the biotinylation procedure.
Slices were then cooled and treated with NHS-SS-Biotin (1 mg/ml,
Thermo Scientiﬁc) for 1 h at 4 C. The biotin reaction was
quenched with glycine buffer containing 192 mM Glycine and
25 mM Tris (pH 8.3). Slices were then homogenized in lysis buffer(pH 8.0) containing 50 mM Tris, 150 mM NaCl, 1 mM EDTA, 1 mM
NaF; and the following protease inhibitors: 1 mM PMSF, 10 mg/mL
aprotinin, 10 mg/mL pepstatin A, 10 mg/mL leupeptin, 2 mM
Na3VO4, 20 mM sodium pyrophosphate, 3 mM benzamidine hy-
drochloride, and 4 mM glycerol 2-phosphate with 1% NP-40
detergent.
A Bradford Assay determined protein concentration in the ly-
sates, and 500 mg of protein lysate diluted in lysis buffer was
loaded into Streptavidin agarose beads (Thermo Scientiﬁc) and
rotated overnight at 4 C. The proteins were eluted by adding
50 ml of 2X Laemmli sample buffer (Bio-Rad) and boiling the
samples at 95 C for 5 min. Whole cell lysate samples of 50 mg
were eluted in 20 ml of the same Laemmli buffer and boiled for
5 min. Samples were loaded into 10% SDS-PAGE gels and trans-
ferred from gels to Immobilon-PSQ transfer membranes (Milli-
pore, 3 h at 4 C). Membranes were then treated with primary
antibodies overnight at 4 C as follows: monoclonal mouse anti-
GluA1 (1:1000, Millipore), polyclonal rabbit anti-GluA1-pSer831
(1:1000, Millipore), polyclonal rabbit anti-GluA1-pSer845
(1:1000, Millipore), polyclonal rabbit anti-GluA2 (1:1000, Milli-
pore), and monoclonal mouse anti-GAPDH (1:2000, Millipore).
Immunoblots were normalized to either whole-cell lysate levels
of the protein of interest (for biotinylation) or GAPDH (for
pSer831-GluA1 and pSer845-GluA1) as indicated in the
Figure legends. Analysis was performed using Quantity One Basic
(BioRad) and ImageJ (NIH, public domain). Statistical signiﬁcance
was assessed using a one-way ANOVA test and a TukeyeKramer
multiple comparison test using GraphPad InStat version 3.0
(GraphPad).
2.6. Propidium iodide staining
Propidium iodide (PI) is an effective ﬂuorescent marker for cell
death due to the fact that it only enters and labels cells with dis-
rupted plasma membranes (Pugliese et al., 2009). The methods
used were adapted from Pugliese et al. (2009). Hippocampal slices
were pre-incubated in appropriate drug treatments for 1 h, fol-
lowed by 20 min hypoxia and 3 h normoxic washout. In other
studies, 500 nM CPA was applied for 30 min (with or without
45 min pre-incubation with 500 nM DPCPX) followed by a 3 h
washout of the drug(s). In the ﬁnal 1 h, 5 mg/ml PI (Sigma) was
added to the aCSF. Following the incubation period, slices were
rinsed thoroughly and ﬁxed in 4% paraformaldehyde at 4 C over-
night. The following day, slices were washed in 1X PBS and then
mounted on glass microscope slides and treated with Prolong Gold
Antifade Reagent (Invitrogen). After adding PI, all subsequent pro-
cedures were performed in the dark to prevent photobleaching.
Imaging was performed using a Zeiss LSM700 laser scanning
confocal microscope (Carl Zeiss, Germany) using green light
(543 nm) to induce PI ﬂuorescence. The whole hippocampus was
imaged in pieces using a 10 objective lens, and images of CA1
pyramidal neurons were obtained using the Zeiss Plan-Apochromat
63/1.4 oil objective lens (Carl Zeiss). CA1 images were acquired as
Z-stack images of 200 mm depth into the hippocampal slice with
each Z-stack image taken at 2 mm. Two Z-stack images were taken
along CA1 for each slice and were averaged using densitometry
analysis.
Data was collected using Zeiss Zen 2009 version 5.5 software
(Carl Zeiss) and was analyzed using ImageJ. Z-stack images closest
to the outer top and bottom of the hippocampal slices were not
analyzed, as the neuronal damage in those areas was enhanced by
the slicing procedure. An inner section of 20 mm (~100 mm deep)
was analyzed using densitometry analysis. Full hippocampal im-
ages were assembled as montages of the entire hippocampal slice
using Adobe Photoshop CS6 (Adobe Systems, Mountain View, CA).
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3.1. Inhibition of PP1, PP2A and PP2B prevented CPA-induced GluA1
internalization, whereas only PP2A inhibition prevented GluA2
internalization
We ﬁrst sought to test the effect of A1R activation in hippo-
campal slices that were pre-incubated in PP1, PP2A, and PP2B in-
hibitors for 1 h followed by a 30 min treatment with the A1R
agonist CPA (500 nM). We found in previous studies (Brust et al.,
2007, 2006; Chen et al., 2014), that the high concentration of CPA
(500 nM vs. 50 nM) was ideal to produce a stronger activation of
A1R-activated proteins including p38 MAPK, JNK, and PP2A, and to
induce higher levels of AMPAR internalization and subsequent
APSD. We previously showed that the PP2A inhibitors okadaic acid
(20 nM) and fostriecin (20 nM) prevented A1R-induced GluA1 and
GluA2 internalization (Chen et al., 2014). In the present study, we
applied general protein phosphatase inhibitor okadaic acid, PP2A-
selective fostriecin, PP1-selective tautomycetin, and PP2B-
selective FK506 at similar concentrations used by us and others
in previous publications (Chen et al., 2014; Hedou et al., 2008;
Uchino et al., 2002). Resultant Western blots show that hippo-
campal slices treated with tautomycetin, okadaic acid, fostriecin,
and FK506 prevented the CPA-induced GluA1 internalization
(Fig. 1A and B). All biotinylated blots were normalized to whole cell
levels of the proteins of interest. Compared to CPA alone, which
induced approximately 40% reduction in surface GluA1, phospha-
tase inhibitor treatments did not signiﬁcantly alter GluA1 surface
expression compared to control (100%). In contrast, CPA-induced
GluA2 internalization was prevented by okadaic acid and fos-
triecin, but not by tautomycetin or FK506 (Fig. 1A and C). Since the
concentration of okadaic acid used may be selective for both PP2A
and PP1, the effect of okadaic acid was compared to the effect of
either fostriecin or tautomycetin. The results suggest that okadaic
acid mimicked the effects of fostriecin in preventing GluA2 inter-
nalization, suggesting that PP2A activation alone was involved in
CPA-induced GluA2 trafﬁcking. The levels of GluA1 and GluA2 in
whole lysates, when normalized to GAPDH, did not differ signiﬁ-
cantly in the different treatments for control, DMSO, okadaic acid,
fostriecin, tautomycetin, and FK506 (data not shown). These data
indicate that PP2A is involved in A1R-induced GluA1 and GluA2
internalization, whereas PP1 and PP2B are involved in GluA1
internalization but not GluA2 internalization after A1R activation.
3.2. PP1, PP2A and PP2B differentially reduce GluA1
phosphorylation at Ser831 and Ser845
Two C-terminal serine residues of GluA1, Ser831 and Ser845, are
essential regulatory phosphorylation sites for GluA1 trafﬁcking and
function (Oh and Derkach, 2005; Roche et al., 1996). We previously
showed that Ser845 phosphorylation was decreased after treat-
ment with a relatively large dose of the selective A1R agonist CPA
(500 nM) but not with a GABAB receptor agonist baclofen (Chen
et al., 2014). To examine the role of PP1, PP2A and PP2B in A1R-
mediated GluA1 dephosphorylation at both the Ser831 and
Ser845 GluA1 residues, we tested the hypothesis that the phos-
phorylation state of Ser831 and Ser845 is modiﬁed by protein
phosphatase inhibitor pre-incubation (above) before a 30 min CPA
treatment. Western blots probed for phosphorylated GluA1 at
either Ser831 or Ser845 (pSer831 and pSer845) showed that whole-
cell levels of pSer831 and pSer845 were signiﬁcantly reduced after
CPA treatment by 25% and 45%, respectively (Fig. 2). In contrast,
these protein phosphatase inhibitors did not signiﬁcantly alter the
total GluA1 levels (Fig. 2A and C, middle blots), suggesting that the
reduction in surface GluA1 was not attributable to GluA1 proteindegradation but likely to increased clathrin-mediated endocytosis
as previously suggested (Chen et al., 2014).
3.3. PP1, PP2A and PP2B mediate CPA-induced synaptic depression
and APSD in hippocampal CA1
To examine the hypothesis that protein phosphatase inhibition
prevents both CPA-induced synaptic depression and APSDs
observed after CPAwithdrawal, as described previously (Chen et al.,
2014), we performed fEPSP recordings in rat hippocampal slices.
CA1 region fEPSP recordings were evoked from hippocampal slices
pre-treated with protein phosphatase inhibitors (see above) for a
minimum of 1 h prior to recording. In the absence of protein
phosphatase inhibitors, the control (DMSO) slices showed a sig-
niﬁcant synaptic depression with CPA treatment (~80e90% syn-
aptic depression, Fig. 3AeC), which was blunted by pre-incubation
of slices with the protein phosphatase inhibitors (Fig. 3C). Similarly,
in slices pre-incubated in vehicle control, approximately 50e60% of
APSD was induced after a 1 h washout of CPA (Fig. 3A, B, and D).
Compared to control (DMSO), okadaic acid, fostriecin, FK506, and
tautomycetin reduced the APSD levels to approximately 20e30%
(Fig. 3D). Although there was less synaptic depression and APSD in
slices treated with phosphatase inhibitors, a residual APSD was still
observed in protein phosphatase inhibitor-treated slices, indicating
that protein phosphatases, although important, are not the only
proteins involved in APSD generation.
3.4. Both GluA1 and GluA2 surface levels are reduced during
hypoxia and contribute to neuronal damage
Next, to test the hypothesis that the A1R-mediated GluA1 and
GluA2 internalization and accompanying APSDs contribute to
neuronal damage during hypoxia, we ﬁrst conﬁrmed that hypoxia
caused similar changes as the A1R agonist CPA in altering the
trafﬁcking of AMPAR subunits. As shown in Fig. 4A, hypoxia
reduced both GluA2 and GluA1 surface expression. We previously
showed (Chen et al., 2014) that this was likely due to clathrin-
mediated internalization and required A1R activation. Surpris-
ingly, we found that after a 45 min normoxic washout period, the
levels of GluA1 increased while the levels of GluA2 remained
depressed (Fig. 4B). Moreover, the increased GluA1 surface
expression was accompanied by increased pSer831 and pSer845
levels (Fig. 4C). We then tested the hypothesis that the initial
involvement of A1R-mediated protein phosphatase activation and
downregulation of AMPAR surface expression during hypoxia
represents the initial trigger for neuronal damage seen after nor-
moxia-reperfusion.
To determine whether prolonged A1R signaling is sufﬁcient to
cause neuronal damage in hippocampal brain slices, we incubated
slices in 500 nM CPA for 30 min, with or without a 45 min pre-
incubation with the A1R antagonist DPCPX (500 nM). Subsequent
washout of CPA for 3 h revealed signiﬁcantly increased neuronal
damage in all of hippocampal pyramidal neurons, which was
blunted in the presence of DPCPX (Fig. 5A). Similarly, a 20 min
hypoxia followed by a 3 h normoxic washout revealed a signiﬁcant
A1R-dependent neuronal damage (Fig. 5B). Finally, we then tested
whether protein phosphatase activation (shown above to mediate
GluA2 and GluA1 internalization and APSDs) is involved in the A1R-
dependent hypoxia-induced neuronal death. As shown in Fig. 6, the
observed hypoxia-mediated neuronal death was largely prevented
by treatment with inhibitors of PP2A (fostriecin, okadaic acid), PP1
(tautomycetin), and PP2B (FK506). Together, these results suggest
that prevention of the initial A1R-mediated GluA2 and GluA1
internalization, in part by preventing protein phosphatase activa-
tion, may provide signiﬁcant neuroprotection by preventing the
Fig. 1. PP1, PP2A, and PP2B inhibitor treatment reduced CPA-induced GluA1 internalization, and PP2A inhibition reduced CPA-induced GluA2 internalization. (A) Repre-
sentative biotinylated Western blots of hippocampal slices exposed to 30 min CPA treatment (500 nM) with pre-incubation in okadaic acid (20 nM), fostriecin (20 nM), tautomycetin
(20 nM), and FK506 (50 nM). (B) Summary bar graph showing that GluA1 surface expressionwas reduced by approximately 40% after CPA treatment with no other drugs added, and
treatment with protein phosphatase inhibitors for 1 h prior to CPA treatment signiﬁcantly reduced CPA-induced GluA1 internalization. Whole lysates probed for GluA1 showed
constant levels across all treatments. (C) Summary chart for GluA2 expression show that CPA treatment reduced GluA2 surface expression, and treatment with okadaic acid and
fostriecin, PP2A inhibitors, prevented CPA-induced GluA2 internalization, with fostriecin signiﬁcantly preventing GluA2 internalization compared to CPA alone. Treatment with
tautomycetin and FK506 did not prevent GluA2 internalization. Whole lysate levels of GluA2 did not signiﬁcantly change. Whole lysate blots were normalized to intracellular
GAPDH. Graphed values are shown as mean ± SEM, n ¼ 4e6 independent experiments, *P < 0.05, **P < 0.01 and ***P < 0.005.
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AMPARs during hypoxia-reperfusion injury.
4. Discussion
The signaling mechanisms that regulate A1R-mediated AMPAR
trafﬁcking and the functional importance of this regulation in
neurotoxicity are not well elucidated. In this study, we investigated
the role of protein phosphatases 1, 2A and 2B in adenosine A1R-
mediated synaptic depression and hypoxia/reperfusion injury in
rat hippocampal slices, and their role in regulating AMPAR surface
expression. We showed that these three serine/threonine protein
phosphatases mediated A1R-induced GluA2 and GluA1 endocy-
tosis. PP1, PP2A and PP2B inhibition reduced CPA-induced GluA1
internalization, but only PP2A inhibition prevented CPA-induced
GluA2 endocytosis. Accordingly, the levels of GluA1 pSer831 and
pSer845 were reduced following CPA treatment. Speciﬁcally, the
reduction in pSer831 was sensitive to PP1 and PP2B inhibitors,
whereas the reduction in pSer845 was only preventable by treat-
ment of hippocampal slices with PP2A inhibitors. Along with
reducing AMPAR surface expression, prolonged A1R activation
induced APSDs as previously shown (Chen et al., 2014) and
conﬁrmed in the present study, and these changes were blunted bypre-treatments of hippocampal slices in PP1, PP2A or PP2B in-
hibitors. Protein phosphatase activation following A1R stimulation
was shown to promote neuronal damage in both CPA- and hypoxia-
treated hippocampal brain slices. Slices subjected to 20 min hyp-
oxia followed by a 45 min normoxic reperfusion/washout showed
increased surface GluA1, without affecting the decreased levels of
surface GluA2. Together, our results suggest that A1R-mediated
activation of protein phosphatases during hypoxic insult contrib-
utes to the subsequent formation of GluA2-deﬁcient AMPARs and
increased GluA1-containing AMPARs during normoxic reperfusion
injury, which triggers neuronal death.
PP1, PP2A and PP2B have been shown to contribute to the
modulation of excitatory neurotransmission and learning and
memory processes throughout the brain through a multitude of
intracellular mechanisms (Belmeguenai and Hansel, 2005; Lin
et al., 2000; Mulkey et al., 1993). For example, PP1 activity has
been shown tomediate the induction of long term potentiation and
long term depression (Allen et al., 2000; Li and Pan, 2013), and has
been shown to directly regulate AMPA receptors in the brain (Yan
et al., 1999). In addition to previously described A1R-induced in-
crease in active PP2A in hippocampal membrane fractions (Brust
et al., 2006), PP2A has also been shown to mediate multiple func-
tions in the brain which includes direct modulation of AMPARs
Fig. 2. Dephosphorylation of GluA1 at Ser831 and Ser845 is mediated by A1R-induced protein phosphatases 1, 2A and 2B activity. (A) Representative whole lysate blots of
hippocampal lysates treated with okadaic acid (20 nM), fostriecin (20 nM), tautomycetin (20 nM), or FK506 (50 nM) for 1 h prior to additional 30 min CPA treatment and probed
sequentially for pSer831-GluA1, GluA1 and GAPDH. (B) Phosphorylated Ser831 was reduced after CPA treatment, and tautomycetin and FK506 nulliﬁed this effect. GluA1 expression
was not signiﬁcantly different between treatments. (C) Representative blots, sequentially probed for pSer845-GluA1, GluA1 and GAPDH, show that CPA treatment also signiﬁcantly
reduced levels of pSer845, which was prevented by okadaic acid and fostriecin treatment. Tautomycetin and FK506 did not prevent this CPA-induced reduction in pSer845. (D)
Summary bar graphs show that pSer845 was signiﬁcantly reduced by CPA treatment in absence or presence of tautomycetin or FK506, and this reduction was prevented by either
okadaic acid or fostriecin. N ¼ 3 independent blots/experiments. Average values are mean ± SEM, Signiﬁcance values: *P < 0.05, **P < 0.01 and ***P < 0.005.
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regulatory B subunit of PP2A is decreased after focal ischemia,
which indicates increased PP2A activity (Koh, 2011). Finally, PP2B, a
Ca2þ-dependent protein phosphatase, has been implicated in the
induction of neurotoxicity in ischemia (Ankarcrona et al., 1996; Asai
et al., 1999), whereas inhibition of PP2B with FK506 has been re-
ported to be an effective neuroprotective treatment (Bochelen et al.,
1999; Butcher et al., 1997; Sharkey and Butcher, 1994; Uchino et al.,
2002). In this study, we add to the wide list of functions performed
by these three ubiquitous protein phosphatases. Speciﬁcally, our
results suggest that protein phosphatase activation contributes to
the generation of the A1R-induced persistent synaptic depression
(or APSD) observed after prolonged washout of the A1R agonist.
Whether the level of APSDs directly correlates with the level of
subsequent neuronal death remains unclear. However, we found
that several protein phosphatase inhibitors, which were successful
in depressing the APSD levels, were also effective in inhibiting
hippocampal neuronal damage. Our results also suggest that PP2A
activation after A1R stimulation selectively downregulated GluA2
surface expression and mediated GluA1 pSer845 dephosphoryla-
tion. In contrast, PP1 and PP2B inhibitors, though effective in
attenuating the reduction in GluA1 surface expression, were only
effective in preventing GluA1 pSer831 dephosphorylation. There-
fore, different serine/threonine protein phosphatases appear to be
involved in the differential regulation of AMPAR trafﬁcking and
AMPAR phosphorylation levels after A1R stimulation. To rule out
nonspeciﬁc effects of the pharmacological inhibitors used in ourstudy, future studies involving knockdown of genes encoding for
PP2A, PP1 or PP2B are required to further establish or conﬁrm the
requirement of protein phosphatase activation in the A1R-
mediated AMPAR surface trafﬁcking and neuronal cell death in
ischemic conditions. It is also important to identify the upstream
signaling cascades that mediate the A1R-mediated protein phos-
phatase activation, and whether activation of PP1, PP2A or PP2B is
accomplished in parallel or in sequential manner by upstream
mediators.
We recently showed that p38 MAPK and JNK mediated A1R-
induced GluA2, but not GluA1, endocytosis, whereas PP2A was
involved in both GluA1 and GluA2 endocytosis (Chen et al., 2014).
The results of the present study show a novel mechanism by which
adenosine A1R activation increases protein phosphatase activity,
which leads to increased GluA2 and GluA1 internalization during
hypoxic injury. However, we found that a subsequent normoxia-
reperfusion period led to increased phosphorylation of GluA1 at
both Ser831 and Ser845, which is consistent with our observation
of enhanced GluA1 surface expression. This increase in GluA1
surface expression, coupled with the persistent downregulation of
GluA2 surface expression, may play a role in the increased calcium
permeability of surface expressed AMPARs which leads to the
observed increase in hippocampal neuronal death following
hypoxia-reperfusion injury. However, the signaling mechanisms
underlying this increased GluA1 surface expression during reper-
fusion injury remains to be deﬁned. The Ser831 and Ser845 of
GluA1 subunits are known targets of PKC/CaMKII and PKA,
Fig. 3. Synaptic depression in area CA1 is reduced by protein phosphatase 1, 2A, and 2B inhibition. (A) Representative fEPSP traces for each treatment showing a sample trace at
the end (ﬁnal 5 min) of the 20 min baseline recording (1), at the end of 30 min CPA treatment (2), at the end of 1 h washout period (3), and an overlay of the three representative
traces (1 þ 2 þ 3). Each representative trace is an average of the ﬁnal 10 sweeps (5 min) of each of the three parts of the experiment (baseline, CPA, and washout). All recordings
were normalized to their own baseline value (100%). (B) Time-course plots of average fEPSP slopes normalized to baseline (100%). (C) Summary bar graph showing fEPSPs as a
percentage of the baseline recording level at the end of a 30 min CPA treatment. Hippocampal slices treated with CPA and no drug inhibitors (DMSO) showed approximately 75%
synaptic depression. Okadaic acid, fostriecin, tautomycetin, and FK506 incubation for 1 h prior to the experiment signiﬁcantly reduced the amount of synaptic depression caused by
CPA. (D) Summary bar graph of the mean fEPSP slope at the end of the 1 h washout period. DMSO slices recovered by about 20%, with fEPSPs recovering to about 50% of baseline. On
the other hand, the fEPSP slopes for slices treated with protein phosphatase inhibitors was signiﬁcantly higher at the end of the washout period. n ¼ 7e10 slices were recorded for
each treatment group from different rats. Graphed values are shown as mean ± SEM. Signiﬁcance values: * ¼ p < 0.05, ** ¼ p < 0.01, *** ¼ p < 0.001.
J. Stockwell et al. / Neuropharmacology 102 (2016) 254e265260respectively (Esteban et al., 2003; Gu et al., 1996; He et al., 2011).
Previous reports also suggested that A1R activation leads to
increased translocation of speciﬁc PKC isoforms to cardiac myocyte
lipid raft microdomains (Yang et al., 2009) and that A1R activation
causes PKC-mediated increase in nucleoside transporter surface
expression and function in porcine epithelial cell lines (Hughes
et al., 2015). Moreover, in hippocampal brain slices, A2AR activa-
tion has been reported to increase the function of adenosine
nucleoside transporters through a PKC-dependent process (Pinto-
Duarte et al., 2005). Therefore, based on these previous studies, it
is possible that the enhanced pSer831 GluA1 levels may be related
to activation of either A1R or A2AR or simultaneous activation of
both receptors, which leads to indirect activation of PKC and sub-
sequently increased pSer831 GluA1 subunits. On the other hand,
A2AR activation has been previously shown to cause increased
hippocampal GluA1, but not GluA2, surface expression (Chen et al.,
2014), as well as PKA-dependent increase in pSer845 GluA1 levels
and GluA1-mediated AMPAR currents (Dias et al., 2012). In addi-
tion, in our in vivo focal cortical stroke model using the pial vessel
disruption procedure (Cayabyab et al., 2013; Chen et al., 2014), we
observed increased A2AR surface expression, but decreased A1R
surface expression, two days after the pial vessel disruption strokeinjury. Together, our results showing increased levels of pSer831
and pSer845 GluA1 subunits after normoxic/reperfusion injury
may be attributable to indirect activation of both PKC and PKA by
different levels of A1R and A2AR stimulation. Our results also
suggest that the prior A1R stimulation during hypoxic insult (or
during direct A1R activation with CPA) and the concomitant acti-
vation of serine/threonine protein phosphatases constitute the
initial trigger for the A1R-mediated decrease in GluA2 and GluA1
surface expression and the generation of APSDs, which contribute
to neuronal damage. However, it will be important in future studies
to further identify the pro-neurotoxic signaling pathways activated
by A1R stimulation that may impact A1R and A2AR trafﬁcking and
signaling to AMPAR subunits.
The precise contribution of serine/threonine protein phospha-
tases in A1R-mediated neurodegeneration in hypoxic/ischemic
injury has not been reported. Previous studies have described the
involvement of the serine/threonine protein phosphatases in
various ischemia-induced cellular mechanisms in the brain (Cid
et al., 2007; Don Yi and Simpkins, 2008; Runden et al., 1998). For
example, PP1, PP2A, and PP2B were shown to play a role in
estrogen-mediated neuroprotection in ischemia, where estrogen
was observed to promote maintenance of the protein expression
Fig. 4. Hypoxia induces decreased GluA1 and GluA2 surface expression, while after normoxic reperfusion, only GluA1 levels increase, which corresponds to increased
pSer831 and pSer845. (A) Western blots showing GluA2 and GluA1 expression immediately following a 20 min hypoxic insult to hippocampal slices (left). Following 20 min
hypoxia, GluA1 and GluA2 surface levels (biotinylated fractions) are signiﬁcantly decreased (right, summary bar charts). (B) After the hypoxic insult, slices that were reintroduced to
oxygenated solution for 45 min also showed a signiﬁcant increase in GluA1 surface expression and a persistent decrease in GluA2 surface expression. (C) The same hippocampal
slices following 45 min normoxic reperfusion also showed signiﬁcantly increased GluA1-pSer831 and pSer845. n ¼ 4e6 independent blots. Graphed values are shown as
mean ± SEM. Signiﬁcance values: * ¼ p < 0.05, and ** ¼ p < 0.01.
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transient middle cerebral artery occlusion stroke model (Don Yi
and Simpkins, 2008). However, it remains unclear whether this
neuroprotective effect of estrogen on ischemic stroke is linked to
maintained protein expression, phosphorylation status, or function
of glutamate receptors, including AMPARs and NMDARs. Another
previous report (Zhu et al., 2012) suggested that simvastatin can
also promote neuroprotection in ischemic stroke by reducing Ca2þ
inﬂux through NMDARs and increasing expression levels of PP2A.
In in vitro ischemic models, oxygen glucose deprivation andsubsequent normoxic reperfusion have been shown to cause
increased expression of Ca2þ-permeable AMPARs (Dias et al., 2013)
and increased levels of neuronal damage (Pugliese et al., 2009),
which can be prevented by administration of an A2AR antagonist
SCH 58261. Dias and colleagues also reported an A2AR-dependent
increase in GluA1 surface expression and GluA1-mediated AMPA
currents, which were accompanied by increased pSer845 levels
(Dias et al., 2012). In the present study, the 20min hypoxia followed
by a 45 min normoxic reperfusion led to persistent downregulation
of GluA2 surface expression but produced an increase in GluA1
Fig. 5. Adenosine A1R activation with CPA or endogenous adenosine receptor stimulation during hypoxia produced signiﬁcant neuronal death in hippocampal slices, which
was prevented by pre-treatments with A1R antagonist DPCPX. (A) Representative confocal microscopy images showing propidium iodide (PI)-labeled hippocampal slices
subjected to a 30 min CPA treatment (500 nM). Signiﬁcant neuronal death was seen with CPA treatment alone, but DPCPX (500 nM) pre-treatment was sufﬁcient to signiﬁcantly
prevent this neuronal death. Summary bar graph (right) shows relative densitometry values for PI ﬂuorescence compared with neuronal death caused by CPA (100%). (B) PI-stained
hippocampal slices that were treated with 20 min hypoxia also showed signiﬁcant neuronal death, which was also prevented by pre-treatment with 500 nM DPCPX. n ¼ 5 in-
dependent experiments, using 5 rats per experiment. Scale bars: 1 mm (whole hippocampus, left column) and 10 mm (CA1, right column, boxed region in left column) apply to A and
B. Values are shown as mean ± SEM. Signiﬁcance values: *** ¼ p < 0.005.
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raising the possibility that decreased protein phosphatase activity
or localization to synaptic sites and/or increased A2AR activation
may also lead to the formation of Ca2þ-permeable AMPARs and
subsequently enhanced hypoxia-reperfusion injury. Additionally,
hypoxia-inducible factors (HIFs), which have increased activity in
hypoxia, have been suggested to interact with the adenosine
signaling pathway in immune cells (Sitkovsky et al., 2004). This
interaction may also occur through A1R/A2AR-dependent activa-
tion of MAPK's, which may activate HIF-1a in cultured neuronal
cells (Thauerer et al., 2012). Since we previously showed that A1Ractivates p38 MAPK and JNK, future studies are required to deter-
mine whether MAPK activation using A1R agonists or hypoxia in
hippocampal slices also result in HIF-1a activation. Whether this
leads to neuroprotection or neurodegeneration remains to be
elucidated.
Together, these in vivo and in vitro models of cerebral ischemia
suggest that decreased levels of serine/threonine protein phos-
phatases may contribute to protracted hyperphosphorylation of
target substrates, including AMPARs. However, future studies are
required to conﬁrm whether a prior activation of A1Rs during
hypoxia then triggers the subsequent A2AR-dependent stimulation
Fig. 6. Protein phosphatase inhibitor pre-treatment reduced neuronal damage in hippocampal slices following 20 min hypoxia. (A) Propidium iodide (PI)-labeled hippo-
campal slice montages show representative slices for each treatment group. Control (DMSO) hypoxia slices showed high levels of neuronal death in the dentate gyrus and CA3-CA1.
Protein phosphatase inhibitors all reduced PI-labeling of hippocampal pyramidal neurons. The inset panels (shown as boxed region in montages) show representative Z-stack
images of CA1 and highest levels of PI labeling in hypoxia alone treated slices. Slices treated with tautomycetin (20 nM), okadaic acid (3 nM), fostriecin (20 nM) or FK506 (50 nM)
showed signiﬁcant attenuation of PI-labeling of hippocampal pyramidal neurons. (B) Summary bar graph showing mean CA1 densitometry values normalized to the time control
values (100%). Representative Z-stack images are shown as a maximum intensity image of 20 mm inside 400 mm-thick hippocampal slices. n ¼ 6 independent experiments, using at
least 5 rats per experiment. Scale bars: 1 mm (whole hippocampus, large image) and 10 mm (CA1, small image, upper right corner) apply to all confocal images. Values are shown as
mean ± SEM. Signiﬁcance values: * ¼ p < 0.05, ** ¼ p < 0.01, *** ¼ p < 0.001.
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If so, these data would indicate a novel mechanism that not only
GluA1-containing AMPARs and A2ARs are key mediators of reper-
fusion injury to neurons by inducing increased Ca2þ permeability of
AMPARs, but also that persistent A1R-mediated downregulation of
GluA2-containing AMPARs (i.e., calcium-permeable) are also crit-
ical for promoting neurotoxicity.
5. Conclusion
In summary, our studies have shown an A1R-mediated differ-
ential regulation of AMPAR subunit expression during and after
hypoxia that contributes to increased vulnerability of hippocampal
neurons to ischemic damage. We have shown that protein phos-
phatase inhibitors reduced A1R-mediated AMPAR internalization
and APSDs. However, our results with hypoxia and subsequent
reperfusion revealed a persistent downregulation of GluA2 surfaceexpression, whereas GluA1 was upregulated only during reperfu-
sion. Although these changes in AMPAR subunits would be pre-
dicted to lead to increased neuronal death, as we have shown in this
study, it is surprising that these changes appeared to depend on a
prior A1R activation (during hypoxia). Future studies are needed to
determine whether a possible cross-talk between A1R and A2AR
exists to modulate AMPAR trafﬁcking and neuronal death in
ischemia. In addition, since we recently found that p38 MAPK and
JNK can also mediate A1R-induced GluA2 internalization (Chen
et al., 2014) and protein phosphatase inhibition alone produced
incomplete prevention of APSDs and neuronal damage (present
study), future studies will be needed to determine whether inhi-
bition of these MAPKs in combination with protein phosphatase
inhibition can be a viable treatment option for ischemic brain
damage. Therefore, this previously unrecognized role of A1R-
mediated excitotoxic potential caused by altering AMPAR subunit
compositions that promote hippocampal neuronal death in
J. Stockwell et al. / Neuropharmacology 102 (2016) 254e265264hypoxia-reperfusion injury, represents a novel therapeutic target in
cerebral ischemic damage.
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